Cool site pour acheter des pilules Ne pas se perdre venir sur.

Microsoft word - llovet jm biosketch 2011-tisch institute _2_.doc

Principal Investigator/Program Director (Last, first, middle): Llovet, Josep M. BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
Professor of Research, University of Barcelona. JLLOVET EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) Autonomous University of Barcelona,Spain
Josep M Llovet, M.D, PhD
, is a co-leader of the HCC program and member of the Tisch Cancer Institute Basic
Translational Research Committee and the Executive Management Committee. Dr. Llovet is a Professor of Medicine and
Director of the Liver Cancer Research Program at Mount Sinai. He has devoted the last 15 years of his career to the study
of the molecular pathogenesis and treatment of liver cancer. He is an unparalleled authority on the clinical development of
novel treatments for HCC, having led the highly successful SHARP trial as the International PI that established sorafenib
as the first molecularly targeted therapy approved for the treatment of HCC. In addition to his NIH funded studies
establishing new molecular classifications of HCC, he initiated and oversees the International HCC Consortium, a
consortium of basic and translational researchers, including Dana-Farber- MIT (Boston), Hospital Clinic (Barcelona) and
National Cancer Institute (Milan). Through these efforts, his research teams have defined new molecular classifications of
HCC based on integrative genomics approaches that incorporate genomic, transcriptomic, proteomic and epigenetic
information to define oncogenic drivers and predictors of outcome in patients with HCC. Dr. Llovet is currently
international PI on 3 major pivotal trials assessing adjuvant and primary treatments of HCC, and oversees highly active
translational research programs at Mount Sinai.
Attending physician. Hospital Clinic, Barcelona Resident. Specialty Board in Gastroenterology. Digestive Disease Department. Hosp. Germans Trias i Pujol (Barcelona). Research Fellow in Hepatology. Hospital Germans Trias Pujol. Barcelona, Spain. Faculty in Digestive Disease. Catalan Institut of Health. Area 8, Barcelona, Spain. Faculty in the Liver Unit, Hospital Clínic Barcelona. Spain. Researcher. Liver Unit. IDIBAPS. Hospital Clinic Barcelona, Spain. Senior researcher . Liver Unit. IDIBAPS. Hospital Clinic Barcelona, Spain. Senior Scientist. Division Liver Diseases and RM Transplantation Institute. Mount Sinai Medical Center, New York, NY. Associate Professor of Medicine. Division Liver Diseases. Mount Sinai School of Medicine Director, HCC Research program. . Mount Sinai School of Medicine. Professor of Research-ICREA. IDIBAPS, Liver Unit. Hospital Clinic Barcelona Executive Secretary. International Liver Cancer Association Visiting Professor, Fudan University, Shangai Professor of Medicine, Division Liver Diseases. Mount Sinai School of Medicine, NYC
Degree in Medicine and Surgery. University of Barcelona (Spain) Speciality Board in Gastroenterology and Hepatology. Doctoral degree in Medicine. Autonomous University of Barcelona. Accreditation as Associate Professor of Medicine (Education Ministry-Spain , AQU-Generalitat Catalunya) Accreditation as Full Professor of Medicine (AQU-Generalitat Catalunya)
Member, Spanish Association for the Study of the Liver. Best communication award. International Association for the Study of the Liver. Member, European Association for the Study of the Liver (EASL). Extraordinary award of Doctoral Thesis: Spontaneous bacterial peritonitis in cirrhosis.”
Member, American Association for the Study of the Liver. Best Article Award 1999-2000: Catalan Foundation for Transplant and the Royal Academy of Medicine of Catalonia. Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): Llovet, Josep M. Llovet JM, Fuster J, Bruix J. Hepatology 1999;30:1434-1440. Member of the “International Task Force on Early Diagnosis of Cancer”. European School of Oncology Expert Reviewer, Agencia Nacional de Evaluación (ANEP), Ministry of Education, Spain. Expert Reviewer, European Association for the Study of the Liver. 2002- Best published article in international peer-reviewed journals from an Spaniard researcher. Ediciones MAYO. Llovet JM, Real MI, Montaña X, et al The Lancet 2002;359:1734-39 Jury member, European Association for the Study of the Liver, 37th Annual Meeting. Madrid. Member of the Academic Committee of the Spanish Association of the Study of the Liver. Grant. Spanish Association for the Study of the Liver “Hernández Guío”. International research project . Grant. Agencia Gestió Ajuts Universitaris de Recerca, 2003BEAI400138. International research project . 2003.- Grant. Societat Catalana de Digestologia. International research project . 2004.- Associate Editor of Journal of Hepatology 2004-2008. Editor in Chief: Prof Massimo Colombo. 2004- Reviewer for the Council for Development Research (RUF), Danish Ministry of Foreig Affers. Reviewer of the Council for Grant support, University Grants Committee of Hong Kong. Member American Association for Cancer research-AACR. Member of the Strategic Planning Initiative for Mount Sinai Medical Center-Liver Cancer Center. Member, Steering Committee of the Early Detection Research Network. National Cancer Institute, USA Reviewer for the AIRC (Associazione Italiana per la Ricerca sul Cancro), Italy Member of the Panel of Experts in hepatocellula carcinomafor the EASL-AASLD-JSH. Reviewer AASLD and EASL comunications for Annual meetings (2005-08) 2006- Associate Editor of Liver transplantation 2006-. Editor: Prof Jorge Rakela 2005. Director, AASLD Single Topic Conference. Design of clinical trials in HCC. Secretary, Panel of experts. 2007 Editorial Board of Hepatology. 2007 Award, Excellence in Research. College of Physicians, Barcelona. 2009- Senior Editor. Clinical Cancer Research (American Association Cancer Research, AACR). Reviewer, National Cancer Institute (NIH) -EDRN. AACR-Landon Award of International Collaboration. Editor: Journal Hepatology. Section: Hepatology Elsewhere Editor: Gastroenterology. Section. Selective Summaries. Seminars in Liver Diseases. Topic: Hepatocellular Carcinoma 2011 Chairman, EASL-EORTC Guidelines of management of HCC.
SELECTED RELEVANT PUBLICATIONS (out of 155; Impact factor SCI : 1346, total number of citations 12530; H index : 50)

1. Follo A, Llovet JM, Navasa M, et al. Renal impairment following spontaneous bacterial peritonitis in cirrhosis. Incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
JM, Bartolí R, Planas R, et al. . Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 1996;23:781-787.
3. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis in cirrhosis. Gastroenterology 1996;111:1011-1017.
JM, Bruix J, Fuster J, Castells A, et al. Liver transplantation for treatment of small hepatocellular carcinoma: The TNM classification does not have prognostic power. Hepatology 1998; 27:1572-1577.
5. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma. Results of a randomized controlled trial in a single institution. Hepatology 1998;27: 1578-1583.
JM, Bustamante J, Castells A, et al. J. Natural history of untreated nonsurgical untreated hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999: 29:62-67.
JM, Fuster J and Bruix J, for the BCLC Group. Intention to treat analysis for surgical treatment of hepatocellular carcinoma: resection vs transplantation. Hepatology 1999;30:1434-1440.
JM, Sala M, Castells Ll, Suarez J, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
9. Sarasin F, Majno P, Llovet JM, Mentha J, Bruix J, Hadengue A. Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness persepctive. Hepatology 2001;33:1073-1079 .
10. Llovet JM, Vilana R, Brú C, et al. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-1129.
11. Llovet JM, Real MI, Montaña X, et al. Arterial embolization or chemoembolization vs symptomatic treatment in patients with unresectable HCC: a randomized controlled trial. The Lancet 2002;359:1734-39
12. Llovet JM, Mas X, Aponte J, et al. BCLC Group. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation. Gut 2002; 50:123-28.
13. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without fibrosis. a simple predictive model. Hepatology 2002; 36:986-992.
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
15. Burrel M, Llovet JM, Ayuso C , et al. MRI angiography is superior to triphasic helical CT for detection of small HCC prior liver transplantation. Comparison with pathologic correlation. Hepatology 2003;38:1034-42.
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): Llovet, Josep M. 16. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004 , 40;1352-1360.
17. Llovet JM, Chen Y, Wurmbach W, et al. A molecular signature to discriminate dysplastic nodules and early hepatocellular
carcinoma in HCV-cirrhosis. Gastroenterology 2006; 131:1758-1767.
18. Mazzaferro V, Romito R,. Schiavo M, Mariani L, Camerini T,Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Adjuvant α-Interferon Treatment after Resection of Hepatocellular Carcinoma in HCV-related
Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence.Hepatology; 2006; 44:1543-54.
19. Wurmbach E, Chen Y, Khitrov G, Roayaie S, Fiel I, Schwartz M, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide profiles of dysplasia and HCC in HCV -cirrhotic patients. Hepatology, 2007, 45: 938-47.
20. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Sala M, Varela M, Llovet JM, Bru C, Bruix J.Diagnosis of hepatic nodules < 20 mm in cirrhosis. Prospective validation of the AASLD guidelines for Hepatocellular Carcinoma (HCC). Hepatology
2008; 47: 97-104.
21. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shirasawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman S. Ras Promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in
hepatocellular carcinoma. Gastroenterology 2008;134:1521-31.
22. Llovet, JM , Di Bisceglie A, J Bruix J, Kramer B, Lencioni R, Zhu A, Sherman M, Schwartz M, Lotze M, Talwalkar J, and Gores GJ on behalf of Panel of Experts in HCC. Design and end-points of clinical trials in HCC. J Natl Cancer Inst 2008;100: 698-711.
23. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
24. Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Martignetti J, Marsh W, Llovet JM. Liver Transplantation for
hepatocellular carcinoma: extended indications based on molecular markers. J Hepatol 2008;49:581-8.
25. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman
SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma.
Cancer Research 2008; 68:6779-88.
26. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada
H, Llovet JM, Golub TR. Gene Expression in fixed tissues and outcome in Hepatocellular Carcinoma. N Engl J Med.
27. Villanueva A, De Feo A, Chen Y, Yea S, Fiel I, Thung S, Schwartz M, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Role of
dual TKI and an mTOR inhibitor in blocking PI3K pathway in HCC. Gastroenterology 2008; 135:1972-83.
28. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting Survival after Liver Transplantationin Patients with Hepatocellular Carcinoma beyond the Conventional Milan/UNOS Criteria. Lancet Oncology 2009;10:35-43
29. Yoo B, Emdad L, Su Z, Villanueva A, Chiang D, Mills AS, Waxman S,. Fisher R, Llovet JM, Fisher P, Sarkar D. Identification of a novel regulator of HCC. J Clin Invest 2009;119:465-77.
30. Keng V, Villanueva A, Chiang D,. Starr T, Silverstein K, Akagi K, Tessarollo L, Matise I, Sarver A, Powers S,. Lowe S,. Col ier L,. Dupuy A,Jenkins N,. Copeland N, Llovet JM, Largaespada D. A conditional transposon-based insertional mutagenesis system
for modeling human cancer in mice. Nature Biotech 2009 ;27:264-74
31. Viswanathan SR, Powers J, Einhorn W, Hoshida Y, Toffanin S, Mermel C, Lu J, Shah SP, Beroukhim R, Tanwar P, Azam M, Perez-Atayde A, Teixeira J, Meyerson M, Frazier L, Mullighan C, Radich J, Llovet JM, Golub TR, and Daley GQ. Lin28 enhances
tumorigenesis and is associated with advanced human malignancies. Nature Genetics 2009; 41:843-8.
32. Sasan Roayaie, Iris N. Blume, Swan N. Thung, Maria Guido*, Maria-Isabel Fiel, Spiros Hiotis, Daniel M. Labow, Josep M. Llovet, Myron Schwartz. Novel Classification of Microscopic Vascular Invasion in Resected Hepatocellular Carcinoma.
Gastroenterology 2009; 137:950-5.
33. Hoshida Y, Nijman S, Kobayashi M,. Chan J, Jean- Brunet P, Chiang D, Villanueva A, Newell P,Ikeda K, Hashimoto M, Watanabe G, Gabriel S,Friedman S, Kumada H, Llovet JM , Golub T. Integrative Transcriptome Analysis Reveals Common
Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009;69:7385-92
34. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung S, Bruix J, Newell P, Roayaie S, Mazzaferro V, Schwartz M, Golub T,. Llovet JM. Outcome Prediction of Hepatocellular Carcinoma
by Modeling Genomic Profiling and Clinical Data. Gastroenterology 2011;140:1501-1512
35. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A., Cabellos L, Minguez B, Savic R, Ward S, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, April C, Fan JB, Schwartz M, Bruix J, Friedman SL, Golub T, Mazzaferro V, Llovet JM. Gastroenterology

36. Llovet JM, Bruix J, Gores G. Surgical resection vs transplantation for early hepatocellular carcinoma: Clues for the best strategy.
Hepatology 2000;31:1919-1921.
37. Llovet JM, Wurmbach E. Gene expression profiles in HCC:not yet there. J Hepatol 2004; 4:336-9.
38. Fattovich G, Llovet JM. Risk factors for HCC in HCV-cirrhosi: what we know and what we miss. J Hepatol 2006:44:1013-1016.
39. Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst.
40. Llovet JM, Bruix J. Testing molecular therapies in HCC: the need of randomized phase II studies. J Clin Oncol, 2009;27:833-5
41. Villanueva A, Savic R, Llovet JM. Lymphotoxins: Novel targets for HCC. Cancer Cell 2009;16:272-273.
42. Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for HCC. Gastroenterology 2010


Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle): Llovet, Josep M. 43. Llovet JM, Brú C, Bruix J. Barcelona-Clínic Liver Cancer Group. Prognosis of hepatocellular carcinoma:The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
44. Bruix J, Sherman M, Llovet JM, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430.
45. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
46. Llovet JM, Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol 2003;38 Suppl 1:S136-49.
47. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma: The Lancet 2003; 362:107-17.
48. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell, 2004;5:215-219.
49. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004 ;127:S179-S188.
50. Llovet JM, Schwartz M Mazzaferro V,. Resection and transplantation for HCC. Sem Liv Dis 2005; 2:181-200.
51. Lopez P, Vil anueva A, Llovet JM. Up-dated systematic review of randomized controlled trials in hepatocellular carcinoma. 2002-2005.
Alim Pharmacol Ther 2006;23:1535-47.
52. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects on diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006, 25; 3848-56.
53. Llovet JM., Schwartz M, Fuster J, Bruix J. Expanding criteria for HCC through downstaging prior liver transplantation: not yet there. Sem Liv Dis 2006, 26:248-53.
54. Lemmer E, Friedman S, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Sem Liv Dis 2006;26:373-384.
55. Villanueva A, Newel P, Chiang D, Friedman S, Llovet JM. Genes and signaling pathways involved in the pathogenesis of HCC. Sem
Liv Dis 2007 2007; 27: 55-76.
56. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008;48: S20-S37.
57. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine:
preliminary steps. Curr Opin Oncol. 2008;20:444-53
58. Newell P, Villanueva A, Friedman S, Koike K, and Llovet JM. Experimental models in hepatocellular carcinoma. J Hepatol, 2008,
59. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
60. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. The Lancet 2009;373:614-16
61. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011:1410-26
62. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet 2011 (in press)

GRANT SUPPORT (Last 5 years):
Institution /Title/Budget
Principal Investigator Period
Genomic predictors and oncogenic drivers in HCC (HEPTROMIC) (3M Euros) National Institute of Health-USA (NIDDK). 1R01DK076986-01. Integrative genomic analysis in hepatocellular carcinoma Samuel Waxman Cancer Research Foundation. New York.USA “Gene expression profiles in preneoplastic lesions and HCC” Bayer Pharmaceuticals, Connecticut,USA. A phase III double-blinded placebo-controlled trial of sorafenib for advanced HCC. ($350,000) National Health Institute, Spain. I+D Program (SAF-2007-61898) Llovet (PI) Adjuvant HCC therapy; A phase III double-blinded placebo-controlled trial of sorafenib. National Institute of Health-USA (NIDDK). 1R01DK080789-01A1. Sadler Edepli (PI). Role of UHRF1in liver development, regeneration and carcinogenesis. ($2,1 M) Bayer Pharmaceuticals, Connecticut,USA. Biomaker study for identification of responders to sorafenib. Phase III randomized, study of brivanib vs placebo in patients failing sorafenib treatment in HCC. Bayer Pharmaceuticals, Connecticut,USA. Phase II randomized, placebo-controlled study of TACE-sorafenib vs TACE-placebo. Biographical Sketch Format Page



Tore Eliasson Curriculum vitae !!! Examen, legitimation, specialistkompetens b. Läkarlegitimation 1986-11-28 c. Specialistkompetens i al män internmedicin 1991-06-03 d. Specialistkompetens i hjärtsjukdomar/kardiologi 1995-03-17 e. Specialistkompetens i smärtlindring (pain medicine) 1997-10-30 !!! Medicine doktorsexamen !Med dr, Hjärt-lunginstitutionen, Göteborgs universitet, 1994

Microsoft word - intentionalqueryexpansion_0501_cr-copy_changes_off_ms.doc

Intentional Query Suggestion: Making User Goals More Explicit During Search ABSTRACT ~25% of queries have a clear navigational intent, and up to ~75% The degree to which users’ make their search intent explicit can of queries need to be understood as informational or transactional be assumed to represent an upper bound on the level of service queries, meaning they are not directed

Copyright © 2010-2014 Predicting Disease Pdf